Wayne interview with The Market Herald, page-7

First 7 Last

Share
Profile

Follow
redant

3,219 Posts.

252

11/03/22

09:19

Post #: 60130274
Share

Originally posted by Eire2011: ↑

Anteris Technologies (AVR) has launched a US$20 million (A$27.5 million) placement to US-based investment management firm Perceptive AdvisorsThe healthcare stock penned an agreement with Perceptive Life Sciences Master Fund for the placement, which will see Perceptive become Anteris’ largest shareholderAnteris will issue 1.84 million shares at $15 each, representing a 20 per cent discount to its last closing price on February 28The funds will be used to develop its 3D single-piece aortic valve replacement, DurAVR, to treat patients with aortic stenosis in upcoming clinical trialsAnteris shares are up 3.11 per cent to trade at $19.25
Anteris Technologies (AVR) has entered a binding agreement with Perceptive Life Sciences Master Fund, managed by Perceptive Advisors, to raise US$20 million (A$27.5 million).
Under the placement, Anteris will issue 1.84 million new shares to the institutional investor at A$15 per share, which represents a 20 per cent discount to AVR’s closing price on February 28.
Founded in 1999, Perceptive Advisors is a New York-based investment management firm
focused on supporting the life sciences industry by identifying opportunities and directing financial resources toward what it deems as promising technologies in modern healthcare.
Upon the completion of this transaction, Perceptive Advisors will be Anteris’ largest shareholder, with an approximate 14 per cent ownership.
Anteris CEO Wayne Paterson said the company “appreciates the confidence Perceptive has in our ground-breaking technology” and was pleased to welcome it as a shareholder.
“We are thrilled to have Perceptive join our shareholder base as the fund’s physician led approach to investing and track record of supporting portfolio companies over the long-term helps ensure we can deliver on the goal of bringing our exceptional TAVR product to market.”
Anteris will use the money from the placement to develop its 3D single-piece aortic valve replacement, DurAVR, for the treatment of aortic stenosis. The company is working on a clinical study designed to test the safety and feasibility of DurAVR‘s THV system on patients with severe aortic stenosis.
The US-based multicenter, phase two early feasibility study will begin sometime this year as part of Anteris’ goal to get DurAVR approved by the US FDA. The company also hopes to undertake clinical trials in Europe to gain apply for CE Mark approval in 2023.
Anteris was up 3.11 per cent to trade at $19.25 at 1:15 pm AEDT.
Anteris Technologies (ASX:AVR) gets US$20m boost for DurAVR development
,
MCAP $251.2M

0 seconds of 13 minutes, 53 seconds

https://themarketherald.com.au/anteris-technologies-asxavr-gets-us20m-boost-for-duravr-development-2022-03-02/?jwsource=cl

Expand

Thanks Eire. I just picked up on the following statement in the report on the interview -
The US-based multicenter, phase two early feasibility study will begin sometime this year
Is it possible that we will be fast tracked straight to a Phase 2 trial?

AVR Price at posting: $18.10 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

BOE

Boss tanks -42% after quietly flagging 'potential challenges' for Honeymoon

Clarity confidence – and share price – up on bumper $203M institutional placement

Monday's HotCopper trends: Boss guidance, Botanix quarterly | July 28

ASX Market Close: New week sees local bourse snaps 2-day losing streak | July 28

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

First 7 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $5.05		Change 0.200(4.12%)		Mkt cap ! $78.29M

Open	High	Low	Value	Volume
$4.86	$5.05	$4.86	$32.22K	6.421K

Buyers (Bids)

No.	Vol.	Price($)
1	454	$4.86

Sellers (Offers)

Price($)	Vol.	No.
$5.05	887	2

View Market Depth

No.	Vol.	Price($)
1	454	4.860
2	2144	4.850
1	882	4.840
1	209	4.780
1	1000	4.750

Price($)	Vol.	No.
5.050	887	2
5.070	200	1
5.150	1212	1
5.200	2136	2
5.220	2066	1

Last trade - 15.32pm 28/07/2025 (20 minute delay)

AVR (ASX) Chart

Wayne interview with The Market Herald, page-7

Boss tanks -42% after quietly flagging 'potential challenges' for Honeymoon

Clarity confidence – and share price – up on bumper $203M institutional placement

Monday's HotCopper trends: Boss guidance, Botanix quarterly | July 28

ASX Market Close: New week sees local bourse snaps 2-day losing streak | July 28

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Wayne interview with The Market Herald, page-7

Top Stories

Boss tanks -42% after quietly flagging 'potential challenges' for Honeymoon

Clarity confidence – and share price – up on bumper $203M institutional placement

Monday's HotCopper trends: Boss guidance, Botanix quarterly | July 28

ASX Market Close: New week sees local bourse snaps 2-day losing streak | July 28

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News